Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea
Understanding the early signs of endometrial cancer coming back is important. Being aware, attending check-ups, and acting ...
Endometriosis and endometrial cancer are conditions that affect a woman's uterus, also called the womb. It's an organ in the lower belly where an unborn baby grows. The two diseases share some things ...
Accumulating evidence suggests that many ovarian high-grade serous carcinomas (HGSCs) originate in the fallopian tube. Malignant cells shed by tubal lesions can be detected by examination of ...
What is the optimal dose and schedule of treatment of endometrial hyperplasia using the various progestins? Is the use of depot medroxyprogesterone a good option for treatment? Patients with ...
Despite widespread provision of Lynch syndrome (LS) screening programs, questions remain about the most effective and efficient protocol for LS case finding. The purpose of this study was to explore ...
Please provide your email address to receive an email when new articles are posted on . Molecular profiling could spare certain patients with high-intermediate risk endometrial cancer adjuvant ...
Endometrial cancer, the most common uterine cancer, often begins with subtle symptoms like abnormal bleeding, which can be ...
Endometrial ablation doesn’t typically affect your weight. However, surgery of any kind may cause changes in your weight. Endometrial ablation is a surgical procedure that involves destroying the ...
1.1 Offer testing for Lynch syndrome to people who are diagnosed with endometrial cancer. Use immunohistochemistry (IHC) to identify tumours with mismatch repair (MMR) deficiency: 1.2 Healthcare ...
In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either ...
Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results